The collaboration between HKIA, HKUMed, and HKSH co-hosted a seminar on "Drug Allergy: Clinical Practices Across the Pacific" on 22 January 2026 in Hong Kong.
This seminar brought together leading experts in the field of drug allergy to compare contemporary approaches to diagnosis and management, with a particular focus on in vitro testing. The seminar also highlighted state-of-the-art methodologies, regional differences in clinical practice, and emerging innovations in allergy diagnostics. Through open dialogue, industry experts Prof. Elizabeth Phillips from Vanderbilt University Medical Center, USA and Dr. Elaine Au from Queen Mary Hospital, Hong Kong shared real-world experience. They discussed the strengths and limitations of current testing strategies and explored opportunities for harmonization and collaboration in advancing safe, evidence-based care for patients with history of severe drug allergies.
The Annual General Meeting for this year took place on 18 November 2025 at Kiangsu Chekiang and Shanghai Residents (HK). Council members and attendees enjoyed an engaging evening.
Dr. Philip Li, the President of HKIA reflected on the institute's evolution into a respected global voice in allergy care, underscored the success of the inaugural EAACI Hong Kong Allergy School. Dr Li also highlighted the 13th Hong Kong Allergy Convention, emphasizied its role in shaping regional standards and advancing integrated patient-centered care. Looking ahead to the 30th anniversary, the commitment to expanding partnerships and enhancing public engagement remains strong, reaffirming HKIA's mission to advance allergy care for patients in Hong Kong and beyond.
The 13th Hong Kong Allergy Convention (HKAC 2025) was successfully held on 18-19 October 2025 at the Hong Kong Convention and Exhibition Centre with the continuous support from the American College of Allergy, Asthma & Immunology (ACAAI) and the World Allergy Organization (WAO).
With the theme of "Allergy Beyond Borders", a series of translational presentations, where laboratory discoveries directly inform clinical practice, and real-world clinical challenges inspire new research directions was conducted. It connected local innovation with global application for the better allergy care.
The Organizing Committee would like to extend their heartfelt gratitude to the Guest of Honour, supporting organizations, all the speakers and sponsors for their unwavering support.
The EAACI Hong Kong Allergy School 2025, a collaborative effort between the Hong Kong Institute of Allergy (HKIA) and the European Academy of Allergy & Clinical Immunology (EAACI), took place successfully on 27-29 August 2025 in Hong Kong. This event marked a significant milestone in allergy education and global collaboration.
Themed "East Meets West", this groundbreaking event brought together the expertise from both Eastern and Western regions. More than 30 distinguished global experts shared cutting-edge insights in the fields of allergy and clinical immunology, enriching the knowledge base of all participants.
One of the highlights of the event was the signing of a Memorandum of Understanding (MOU) between HKIA and EAACI. This agreement symbolizes a crucial step towards fostering collaboration and enhancing the exchange of knowledge and resources in the realm of allergy and clinical immunology. It signifies a commitment to furthering advancements in the field through mutual cooperation and shared expertise.
The Hong Kong Institute of Allergy CSU Symposium, titled "Reimagining CSU Management” was successfully held on 26 August 2025 (Tuesday) at Renaissance Hong Kong Harbour View Hotel, Wanchai.
This event provided the latest advancements and insights in chronic spontaneous urticaria (CSU) management by renowned experts Prof. Zuotao Zhao and Prof. Martin Metz.
The Hong Kong Institute of Allergy and the Hong Kong Society of Rheumatology jointly hosted a Dinner Summit on "IL-5 in T2 Inflammation - Transforming Care in EGPA" on February 24, 2025 (Monday) at the Hyatt Regency in Tsim Sha Tsui.
An exceptional lineup of speakers provided updates on the shared eosinophilic pathways in EGPA and airway diseases, while reviewing the targeted benefits of mepolizumab for both individual and co-morbid conditions.
